Makes treatments for scours and mastitis in cows.
Jun 2026Revenue $30.7M/yrExpenses $26.8M/yr
No trend
Figures by year
Is Immucell profitable?
Yes. In the 12 months to Jun 2026, revenue was $30.7M and expenses $26.8M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $27.6M | $26.0M | $1.65M |
| Dec 2024 | $26.5M | $28.1M | −$1.64M |
| Dec 2023 | $17.5M | $23.2M | −$5.75M |
| Dec 2022 | $18.6M | $20.9M | −$2.30M |
| Dec 2021 | $19.2M | $19.0M | $257K |
| Dec 2020 | $15.3M | $16.7M | −$1.38M |
| Dec 2019 | $13.7M | $14.7M | −$954K |
| Dec 2018 | $11.0M | $12.4M | −$1.45M |
| Dec 2017 | $10.4M | $10.7M | −$243K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.